We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Zhenjiu Lidu and Mhealth both received oversubscriptions and ranked among the top five Hong Kong IPOs by funds raised this year

Zhenjiu Lidu and Mhealth both received oversubscriptions and ranked among the top five Hong Kong IPOs by funds raised this year

 e434f03e6cb4fc9bfee3be7165f85cd4_D8qOx2MdhVcjgAAAABJRU5ErkJggg==.png

Zhenjiu Lidu and MedSci Health both received oversubscriptions and will list on the Hong Kong Stock Exchange (HKEX) tomorrow (April 27) via IPO.

Zhenjiu Lidu (06979.HK) will be the largest IPO in Hong Kong so far this year

Beijing-based Baijiu company Zhenjiu Lidu (06979.HK) announced its offering results: the global offering consists of 490,699,800 shares, with a final offer price of HK$10.82 per share (all prices are in Hong Kong dollars unless otherwise noted), raising HK$5.309 billion, making it the largest IPO in Hong Kong so far this year. Each board lot of Zhenjiu Lidu consists of 200 shares, with a 100% allotment ratio for one board lot. The company will be listed tomorrow (April 27).

The Hong Kong public offering tranche’s initial shares available for subscription were oversubscribed. A total of 10,670 valid applications were received, subscribing to a total of 95,061,800 offering shares, equivalent to approximately 1.94 times the total initial shares available under the Hong Kong public offering tranche (49,070,000 shares).

The offering shares initially proposed under the international offering tranche were oversubscribed, equivalent to approximately 3.9 times the total initial shares available under the international offering tranche. The final number of shares allocated to subscribers under the international offering tranche is approximately 441,600,000 shares, equivalent to 90% of the total initial shares available under the global offering tranche (before exercising any over-allotment option). A total of 73,604,800 shares were over-allotted in the international offering. There are 109 subscribers in the international offering.

The net proceeds from Zhenjiu Lidu’s IPO are approximately HK$4.99 billion, allocated as follows: approximately 55.0% will be used to fund the construction and development of production facilities over the next five years, gradually increasing Baijiu production capacity; approximately 20.0% will be used for brand building and marketing over the next five years, aiming to increase brand awareness and cultivate a growing base of loyal consumers; approximately 10.0% will be used to expand sales channels over the next five years, aiming to continuously drive revenue growth; approximately 5.0% will be used for advanced technologies for business operations automation and digitization over the next five years; approximately 10.0% will be used for working capital and general corporate purposes.

MedSci Health (02415.HK) public offering oversubscribed 8.85 times

MedSci Health (02415.HK), one of China’s largest online physician platforms based in Shanghai, announced its offering results: the global offering consists of 6,678,900 shares, with the offer price set at the lower limit of HK$9.10 per share, raising HK$608 million. Each board lot of MedSci Health consists of 250 shares, with a 20% allotment ratio for one board lot, meaning subscribing to 8 board lots guarantees one board lot. The company will be listed tomorrow (April 27).

The Hong Kong offering tranche’s initially proposed shares were significantly oversubscribed. A total of 11,529 valid applications were received, subscribing to a total of 65,779,250 Hong Kong offering shares, equivalent to approximately 9.85 times the total initial shares available under the Hong Kong public offering tranche (6,679,000 shares).

The offering shares initially proposed under the international offering tranche were slightly oversubscribed, approximately 1.47 times the total initial shares available under the international offering tranche. The final number of shares under the international offering tranche is 60,110,000 shares, accounting for approximately 90% of the total initial shares available under the global offering tranche. There was no over-allotment in the international offering. There are 116 subscribers in the international offering.

The company's IPO has secured 6 cornerstone investors, who together subscribed for approximately US$40 million in the offered shares. Among them, Harvest Fund Management subscribed for approximately US$14 million, GF Global subscribed for US$12 million, and Anguo State-owned Assets, Angjiao Investment, Ang Venture Capital, and Qicai Lingfeng, which are ultimately controlled by the Finance Bureau of Anji County, subscribed for US$6 million, US$3 million, US$3 million, and US$2 million respectively.

The net proceeds from the company's IPO are approximately RMB 538 million. Of this amount, approximately 45.0% will be used for business expansion; approximately 35.0% will be used for further technological development; approximately 15.0% will be used for potential investments and acquisitions by the company or for establishing strategic alliances with companies that can generate synergies with the company's business. Approximately 5% will be used for working capital and general corporate purposes.

Originally published on 金盒企业管理集团